Graft Polymer (UK) PLC - Slovenia-based polymer modification and drug delivery systems - Says Slovenian operations recently hit cash flow positive on the back of organic growth of its production contracts.

‘This represents a key financial and strategic milestone for the group,’ it adds.

Also, expects to double capacity at Slovenian production and research facility in ‘coming weeks’.

‘With the achievement of reaching cash flow positive at our Slovenia facility through organic growth alone, the continuous operational developments being made put Graft Polymer in a good position as we deliver on our strategy,’ Chief Executive Victor Bolduev says.

Current stock price: 16.01 pence

12-month change: down 28%

Copyright 2022 Alliance News Limited. All Rights Reserved.